DGI:Perioperative Prophylaxe/Prophylaxe und Prävention: Difference between revisions
imported>Brinkery (Die Seite wurde neu angelegt: „== Prophylaxe/Prävention ==“) |
imported>Bestem No edit summary |
||
| Line 1: | Line 1: | ||
== Prophylaxe/Prävention == | ==Prophylaxe/Prävention== | ||
'''<span style="color: #333333">Endokarditis-Prophylaxe</span>''' | |||
'''<span style="color: #333333">Grundlage:</span>''' | |||
* <span style="color: #333333">2015 ESC Guidelines for the management of infective Endocarditis</span> | |||
* <span style="color: #333333">ask</span> <span style="color: #333333"><span style="letter-spacing:-.1pt">force</span> for the Management <span style="letter-spacing:-.1pt">of</span> Infective Endocarditis <span style="letter-spacing:-.1pt">of</span> the European <span style="letter-spacing:.05pt">Society</span> <span style="letter-spacing: -.1pt">of</span> <span style="letter-spacing:-.05pt">Cardiology</span></span> | |||
'''Wer:''' | |||
* wird nur für Hochrisikopatienten empfohlen | |||
* Hochrisikopatienten sind <span style="letter-spacing:-.1pt">Patienten</span> <span style="letter-spacing:-.05pt">mit</span> <span style="letter-spacing:-.1pt">der</span> höchsten <span style="letter-spacing:.05pt">Inzidenz</span> einer infektiösen <span style="letter-spacing:-.05pt">Endokarditis</span> <span style="letter-spacing: -.2pt">und/oder</span> <span style="letter-spacing:-.05pt">mit</span> <span style="letter-spacing:-.05pt">dem</span> höchsten <span style="letter-spacing:.05pt">Risiko</span> <span style="letter-spacing: .1pt">für</span> einen schlechten <span style="letter-spacing:-.2pt">Verlauf</span> einer infektiösen <span style="letter-spacing:-.05pt">Endokarditis.</span> Dazu <span style="letter-spacing:-.05pt">gehören:</span> | |||
* Patienten mit Klappenprothesen, einschließlich Transkatheterklappen, oder mit rekonstruierten Klappen unter Verwendung prothetischen Materials | |||
* Patienten <span style="letter-spacing:-.05pt">mit</span> <span style="letter-spacing:-.05pt">überstandener</span> <span style="letter-spacing: -.05pt">Endokarditis</span> | |||
* Patienten mit angeborenen Herzfehlern: | |||
# jegliche zyanotischen Herzfehler | |||
# bis zu 6 Monate nach operativer oder interventioneller Vitienkorrektur unter Verwendung von prothetischem Material oder lebenslang bei residuellem Shunt oder Klappeninsuffizienz | |||
* Keine Endokarditis-Prophylaxe <span style="letter-spacing:.1pt">für</span> alle <span style="letter-spacing:-.05pt">anderen</span> <span style="letter-spacing: -.05pt">Formen</span> <span style="letter-spacing:-.1pt">der</span> <span style="letter-spacing:-.05pt">Klappen-</span> <span style="letter-spacing: .05pt">und</span> Herzerkrankungen | |||
'''Wann''' (bei welchen Eingriffen sollten Hochrisikopatienten eine Endokarditis-Prophylaxe erhalten): | |||
* Zahnärztliche Eingriffe | |||
o Endokarditis-Prophylaxe <span style="letter-spacing:-.05pt">empfohlen</span> <span style="letter-spacing:-.05pt">bei</span> <span style="letter-spacing:.05pt">Eingriffen</span> / <span style="letter-spacing:-.05pt">Manipulationen</span> <span style="letter-spacing:.1pt">an</span> <span style="letter-spacing:-.1pt">der</span> <span style="letter-spacing:-.05pt">Gingiva,</span> <span style="letter-spacing: | |||
-.1pt">der</span> periapikalen <span style="letter-spacing:.05pt">Zahnregion</span> <span style="letter-spacing: | |||
-.05pt">oder</span> <span style="letter-spacing:-.1pt">Perforation</span> <span style="letter-spacing:-.1pt">der</span> <span style="letter-spacing:-.05pt">oralen</span> <span style="letter-spacing:-.05pt">Mukosa</span> | |||
o KEINE <span style="letter-spacing:-.05pt">Endokarditis-Prophylaxe</span> <span style="letter-spacing:-.05pt">bei</span> <span style="letter-spacing:-.05pt">Applikation</span> <span style="letter-spacing:-.15pt">von</span> Lokalanästhesie <span style="letter-spacing:.1pt">in</span> reizlosem <span style="letter-spacing:-.1pt">Gewebe,</span> <span style="letter-spacing: | |||
-.1pt">Faden-</span> entfernung, <span style="letter-spacing:-.1pt">Röntgen,</span> Einsatz <span style="letter-spacing:-.05pt">oder</span> <span style="letter-spacing: | |||
-.05pt">Entfernung</span> <span style="letter-spacing:-.15pt">von</span> Zahnprothesen <span style="letter-spacing:-.05pt">oder</span> <span style="letter-spacing: | |||
.05pt">Klammern,</span> <span style="letter-spacing:-.05pt">Lippentrauma</span> <span style="letter-spacing:-.05pt">oder</span> <span style="letter-spacing:-.1pt">Verletzung</span> <span style="letter-spacing: | |||
-.1pt">der</span> <span style="letter-spacing:-.05pt">oralen</span> <span style="letter-spacing:-.05pt">Mukosa</span> | |||
o KEINE <span style="letter-spacing:-.05pt">Endokarditis-Prophylaxe</span> nach <span style="letter-spacing:.05pt">Milchzahnwechsel</span> <span style="letter-spacing:-.05pt">oder</span> <span style="letter-spacing: | |||
-.1pt">Verletzung</span> <span style="letter-spacing:-.1pt">der</span> <span style="letter-spacing:-.05pt">Lippen</span> <span style="letter-spacing: | |||
.05pt">und</span> <span style="letter-spacing:-.05pt">oralen</span> <span style="letter-spacing:-.05pt">Mukosa</span> | |||
* Eingriffe am Respirationstrakt | |||
'''Cave:''' KEINE <span style="letter-spacing:-.05pt">Endokarditis-Prophylaxe</span> <span style="letter-spacing:-.05pt">bei</span> Eingriffen am Respirationstrakt, einschließlich <span style="letter-spacing:-.05pt">Laryngoskopie,</span> <span style="letter-spacing:-.1pt">Bronchoskopie</span> transnasale-, | |||
* <span style="letter-spacing:-.05pt">endotracheale</span> <span style="letter-spacing:-.05pt">Intubation (oral oder nasal)</span> | |||
* Gastrointestinale oder Urogenitale Eingriffe an infizierten Herden | |||
o intraabdominaler Abszess | |||
o Ileus | |||
o Darmperforation | |||
o Magenperforation | |||
o Cholecystitis/ Gallenblasenempyem | |||
o Fourniersche Gangrän | |||
o infizierte Harnstauungsniere | |||
'''Cave:''' KEINE <span style="letter-spacing: | |||
-.05pt">Endokarditis-Prophylaxe</span> <span style="letter-spacing:-.05pt">bei</span><span style="letter-spacing:.05pt">:</span> <span style="letter-spacing:-.1pt">Gastroskopie,</span> <span style="letter-spacing:-.15pt">Coloskopie,</span> transösophageales <span style="letter-spacing:-.1pt">Echo,</span> <span style="letter-spacing:-.1pt">Cystoskopie</span> | |||
* Eingriffe an Weichteilgewebe und Haut | |||
o KEINE <span style="letter-spacing:-.05pt">Endokarditis-Prophylaxe</span> | |||
'''PAP und Endokarditis-Prophylaxe''' | |||
Liegt eine Indikation zur Endokarditis-Prophylaxe vor, <span style="letter-spacing:-.1pt">werden</span> - anstelle <span style="letter-spacing:-.1pt">der</span> oben <span style="letter-spacing: | |||
-.05pt">empfohlenen</span> Antibiotika – <span style="letter-spacing: | |||
-.05pt">bevorzugt</span> Substanzen <span style="letter-spacing:-.05pt">mit</span> <span style="letter-spacing:-.05pt">Enterokokken-Wirksamkeit</span> eingesetzt: | |||
{| class="wikitable" | |||
|+ | |||
!'''Antibiotika zur PAP''' | |||
!Empfohlene (Ersatz-) Substanz bei Indikation zur Endokarditis-Prophylaxe<br /> | |||
|- | |||
|Ohne <span style="letter-spacing:-.15pt">P</span><span style="letter-spacing:-.1pt">AP-Indikation</span><br /> | |||
|Ampicillin 2g <span style="letter-spacing: | |||
-.2pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span><br /> | |||
|- | |||
|Cefazolin / <span style="letter-spacing: | |||
-.2pt">C</span><span style="letter-spacing:-.1pt">efuroxim</span><br /> | |||
|<span style="color: #222222">Ampicillin-</span><span style="color: #222222">Sulbac</span><span style="color: #222222">t</span><span style="color: #222222">am</span> <span style="color: #222222">3g <span style="letter-spacing:-.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span></span><br /> | |||
|- | |||
|Cefazolin / <span style="letter-spacing: | |||
-.2pt">C</span><span style="letter-spacing:-.15pt">ef</span><span style="letter-spacing:-.1pt">ur</span><span style="letter-spacing:-.15pt">o</span><span style="letter-spacing:-.1pt">xi</span><span style="letter-spacing:-.15pt">m</span> + <span style="letter-spacing:-.15pt">Me</span><span style="letter-spacing:-.1pt">tr</span><span style="letter-spacing:-.15pt">o</span><span style="letter-spacing:-.1pt">nid</span><span style="letter-spacing:-.15pt">az</span><span style="letter-spacing:-.1pt">ol</span><br /> | |||
|<span style="color: #222222">Ampicillin-</span><span style="color: #222222">Sulbac</span><span style="color: #222222">t</span><span style="color: #222222">am</span> <span style="color: #222222">3g <span style="letter-spacing:-.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span></span><br /> | |||
|} | |||
{| class="wikitable" | |||
|+ | |||
!'''ß-Laktam-Allergie''' | |||
!Empfohlene (Ersatz-) Substanz bei Indikation zur Endokarditis-Prophylaxe<br /> | |||
|- | |||
|Ohne <span style="letter-spacing:-.15pt">P</span><span style="letter-spacing:-.1pt">AP</span><br /> | |||
|<span style="color: #222222">Cli</span><span style="color: #222222">ndam</span><span style="color: #222222">y</span><span style="color: #222222">cin</span> <span style="color: #222222">600m</span><span style="color: #222222">g</span> <span style="color: #222222">i.</span><span style="color: #222222">v</span><span style="color: #222222">./p.o.</span><br /> | |||
|- | |||
|Cefazolin / <span style="letter-spacing: | |||
-.2pt">C</span><span style="letter-spacing:-.1pt">efuroxim (ohne Gastrointestinaltrakt)</span><br /> | |||
|<span style="color: #222222">Cli</span><span style="color: #222222">ndam</span><span style="color: #222222">y</span><span style="color: #222222">cin</span> <span style="color: #222222">600m</span><span style="color: #222222">g</span> <span style="color: #222222">i.</span><span style="color: #222222">v</span><span style="color: #222222">./p.o.</span><br /> | |||
|- | |||
|Cefazolin / <span style="letter-spacing: | |||
-.2pt">C</span><span style="letter-spacing:-.15pt">ef</span><span style="letter-spacing:-.1pt">ur</span><span style="letter-spacing:-.15pt">o</span><span style="letter-spacing:-.1pt">xi</span><span style="letter-spacing:-.15pt">m</span> +/- <span style="letter-spacing:-.15pt">Me</span><span style="letter-spacing:-.1pt">tr</span><span style="letter-spacing:-.15pt">o</span><span style="letter-spacing:-.1pt">nid</span><span style="letter-spacing:-.15pt">az</span><span style="letter-spacing:-.1pt">ol</span><br /> | |||
|Vancomycin 1g <span style="letter-spacing: | |||
-.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span> + <span style="letter-spacing:-.2pt">C</span><span style="letter-spacing:-.1pt">ipr</span><span style="letter-spacing:-.15pt">ofloxacin</span> 400 <span style="letter-spacing:-.1pt">mg</span> <span style="letter-spacing:-.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span> +/- <span style="letter-spacing:-.15pt">Me</span><span style="letter-spacing:-.1pt">t</span><span style="letter-spacing:-.15pt">ro</span><span style="letter-spacing:-.1pt">nid</span><span style="letter-spacing:-.15pt">azol</span> 500 <span style="letter-spacing:-.1pt">mg</span> <span style="letter-spacing:-.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span><br /> | |||
|} | |||
'''Antibiotika für die perioperative Antibiotika- und Endokarditis-Prophylaxe''' | |||
{| class="wikitable" | |||
|+ | |||
!'''Antibiotikagruppe''' | |||
!'''Substanz''' | |||
!'''Dosis/Applikations-art''' | |||
!'''Zeitpunkt der Gabe''' | |||
!'''Wiederholungsgabe<sup>3)</sup>''' | |||
|- | |||
|Aminopenicillin<br /> | |||
|Ampicillin<br /> | |||
|1 x 2g <span style="letter-spacing: | |||
-.2pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span><br /> | |||
|Infusionsende 30 min vor Schnitt<br /> | |||
|> 3 h <span style="letter-spacing:-.1pt">OP-Daue</span><span style="letter-spacing:-.05pt">r</span><br /> | |||
|- | |||
|<span style="color: #222222">Aminope</span><span style="color: #222222">nicillin</span> <span style="color: #222222">+</span> | |||
<span style="color: #222222">ß</span><span style="color: #222222">-Lakt.-Inhibitor (BLI)</span> | |||
|<span style="color: #222222">Amo</span><span style="color: #222222">xicillin</span> <span style="color: #222222">+ <span style="letter-spacing:-.1pt">Clav</span><span style="letter-spacing:-.05pt">ulan-Säure</span></span><br /><span style="color: #222222">Ampicillin</span> <span style="color: #222222">+ <span style="letter-spacing:-.1pt">Sulbac</span><span style="letter-spacing:-.05pt">t</span><span style="letter-spacing:-.1pt">am</span></span> | |||
|1 x 875/125mg p.o.<br />1 x 3g i.v. | |||
|120 <span style="letter-spacing: | |||
-.05pt">min vor Schnitt</span><sup>1)</sup><br />Infusionsende 30 min vor Schnitt | |||
|> 3 h <span style="letter-spacing:-.1pt">OP-Daue</span><span style="letter-spacing:-.05pt">r</span><br />> 3 h <span style="letter-spacing:-.1pt">OP-Daue</span><span style="letter-spacing:-.05pt">r</span> | |||
|- | |||
|gezielte Carbapenem-Prophylaxe<br /> | |||
|Imipenem <sup>2)</sup> | |||
Meropenem | |||
|1 x 1g <span style="letter-spacing:-.2pt">i.</span><span style="letter-spacing:-.25pt">v</span> | |||
1 x 1g i.v. | |||
|Infusionsende 30 min vor Schnitt<br /> | |||
|> 3 h <span style="letter-spacing:-.1pt">OP-Daue</span><span style="letter-spacing:-.05pt">r</span><br /> | |||
|- | |||
|Cephalosporin Gruppe 1<br /> | |||
|Cefazolin<br /> | |||
|1 x 2g <span style="letter-spacing:-.2pt">i.</span><span style="letter-spacing:-.25pt">v</span> bei KG<br />>120<span style="letter-spacing: | |||
-.15pt">kg</span> 1 x 3g <span style="letter-spacing:-.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span> | |||
|Infusionsende 30 min vor Schnitt<br /> | |||
|> 3 h <span style="letter-spacing:-.1pt">OP-Daue</span><span style="letter-spacing:-.05pt">r</span><br /> | |||
|- | |||
|Cephalosporin Gruppe 2<br /> | |||
|Cefuroxim<br /> | |||
|1 x 1,5g <span style="letter-spacing: | |||
-.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span> | |||
>120<span style="letter-spacing:-.15pt">kg</span> 1 x 3g <span style="letter-spacing:-.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span> | |||
|Infusionsende 30 min vor Schnitt<br /> | |||
|> 3 h <span style="letter-spacing:-.1pt">OP-Daue</span><span style="letter-spacing:-.05pt">r</span><br /> | |||
|} | |||
'''Sonderindikationen''' | |||
{| class="wikitable" | |||
|+ | |||
!'''Antibiotikagruppe''' | |||
!'''Substanz''' | |||
!'''Dosis/Applikations-art''' | |||
!'''Zeitpunkt der Gabe''' | |||
!'''Wiederholungsgabe<sup>3)</sup>''' | |||
|- | |||
|Cephalosporin Gruppe 3a<br /> | |||
|Ceftriaxon<br /> | |||
|1 x 2g <span class="ve-pasteProtect" style="letter-spacing:-.25pt" data-ve-attributes="{"style":"letter-spacing:-.25pt"}">i.</span><span class="ve-pasteProtect" style="letter-spacing:-.3pt" data-ve-attributes="{"style":"letter-spacing:-.3pt"}">v</span><span class="ve-pasteProtect" style="letter-spacing:-.25pt" data-ve-attributes="{"style":"letter-spacing:-.25pt"}">.</span><br /> | |||
|Infusionsende 30 min vor Schnitt<br /> | |||
|> 8 h OP- <span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">D</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">auer</span><br /> | |||
|- | |||
|Fluorchinolon Gruppe 2<br /> | |||
|Ciprofloxacin<br /> | |||
|1 x 500<span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">m</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">g</span> <span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">p.</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">o</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">.</span> | |||
1 x 400mg i.v. | |||
|120 min vor Schnitt<sup>1)</sup> | |||
Infusionsende 30 min vor Schnitt, Infusionsdauer 60 min | |||
|> 8 h OP- <span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">D</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">auer</span><br /> | |||
|- | |||
|Fluorchinolon Gruppe 3<br /> | |||
|Levofloxacin<br /> | |||
|1 x 500<span class="ve-pasteProtect" style="letter-spacing: | |||
-.05pt" data-ve-attributes="{"style":"letter-spacing:\n -.05pt"}">m</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">g</span> <span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">p.</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">o</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">.</span><br /> | |||
|120 <span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">min</span> vor Schnitt<sup>1)</sup><br /> | |||
|> 12 h OP- <span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">D</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">auer</span><br /> | |||
|- | |||
|Glykopetid<br /> | |||
|Vancomycin <sup>3)</sup><br /> | |||
|1 x 1g <span class="ve-pasteProtect" style="letter-spacing:-.2pt" data-ve-attributes="{"style":"letter-spacing:-.2pt"}">i.</span><span class="ve-pasteProtect" style="letter-spacing:-.3pt" data-ve-attributes="{"style":"letter-spacing:-.3pt"}">v</span><span class="ve-pasteProtect" style="letter-spacing:-.25pt" data-ve-attributes="{"style":"letter-spacing:-.25pt"}">.</span><br /> | |||
|Infusionsende 30 min vor Schnitt, Infusionsdauer >60 min<sup>3)</sup><br /> | |||
|> 12 h OP- <span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">D</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">auer</span><br /> | |||
|- | |||
|Folat-Antagonist<br /> | |||
|Cotrimoxazol<br /> | |||
|1 x 960<span class="ve-pasteProtect" style="letter-spacing: | |||
-.05pt" data-ve-attributes="{"style":"letter-spacing:\n -.05pt"}">m</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">g</span> <span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">p.</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">o</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">.</span><br /> | |||
|120 <span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">min</span> vor Schnitt<sup>1)</sup><br /> | |||
|> 12 h OP- <span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">D</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">auer</span><br /> | |||
|- | |||
|Lincosamid<br /> | |||
|Clindamycin<br /> | |||
|1 x 600<span class="ve-pasteProtect" style="letter-spacing: | |||
-.05pt" data-ve-attributes="{"style":"letter-spacing:\n -.05pt"}">m</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">g</span> <span class="ve-pasteProtect" style="letter-spacing:-.25pt" data-ve-attributes="{"style":"letter-spacing:-.25pt"}">i.</span><span class="ve-pasteProtect" style="letter-spacing:-.3pt" data-ve-attributes="{"style":"letter-spacing:-.3pt"}">v</span><span class="ve-pasteProtect" style="letter-spacing:-.25pt" data-ve-attributes="{"style":"letter-spacing:-.25pt"}">.</span><br /> | |||
|Infusionsende 30 min vor Schnitt<br /> | |||
|> 6 h OP- <span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">D</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">auer</span><br /> | |||
|- | |||
|Nitroimidazol<br /> | |||
|Metronidazol<br /> | |||
|1 x 500<span class="ve-pasteProtect" style="letter-spacing: | |||
-.05pt" data-ve-attributes="{"style":"letter-spacing:\n -.05pt"}">m</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">g</span> <span class="ve-pasteProtect" style="letter-spacing:-.25pt" data-ve-attributes="{"style":"letter-spacing:-.25pt"}">i.</span><span class="ve-pasteProtect" style="letter-spacing:-.3pt" data-ve-attributes="{"style":"letter-spacing:-.3pt"}">v</span><span class="ve-pasteProtect" style="letter-spacing:-.25pt" data-ve-attributes="{"style":"letter-spacing:-.25pt"}">.</span><br /> | |||
|Infusionsende 30 min vor Schnitt<br /> | |||
|> 8 h OP- <span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">D</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">auer</span><br /> | |||
|} | |||
<sup>1)</sup> Maximaler Serumspiegel <span style="letter-spacing:.05pt">bei</span> <span style="letter-spacing:.05pt">normaler</span> enteraler <span style="letter-spacing:.05pt">Resorption</span> | |||
<sup>2)</sup> „Imipenem 1g“ entspricht Imipenem 1g + Cilastatin 1g (= 2x 1Ampulle à 0,5g Imipenem + 0,5g Cilastatin) | |||
<sup>3)</sup> Infusionsdauer > 1 h, ansonsten <span style="letter-spacing: | |||
.05pt">Gefahr</span> von „Red-Man-Syndrom“ <span style="letter-spacing: | |||
-.05pt">(Hautrötung</span> <span style="letter-spacing:.05pt">u.</span> <span style="letter-spacing:-.05pt">Schwellung</span> im <span style="letter-spacing:.05pt">Kopf-Hals-Bereich,</span> die <span style="letter-spacing:.05pt">wie</span> eine <span style="letter-spacing: | |||
.05pt">Allergie</span> imponieren kann) | |||
<sup>4)</sup> In Abhängigkeit von <span style="letter-spacing:.05pt">der</span> Halbwertszeit <span style="letter-spacing:.05pt">bei</span> <span style="letter-spacing:.05pt">normaler</span> <span style="letter-spacing:.05pt">Nierenfunktion</span> | |||
<span style="color: #333333">Angaben Halbwertzeiten:</span> ''<span style="color: #333333">Mandell,</span> <span style="color: #333333"><span style="letter-spacing:-.05pt">Douglas</span> and <span style="letter-spacing:.05pt">Bennetts:</span> <span style="letter-spacing: | |||
-.05pt">Principles</span> and Practise <span style="letter-spacing: | |||
-.1pt">of</span> <span style="letter-spacing:.05pt">Infectious</span> Disease.</span> <small>Elsevier <span style="letter-spacing: | |||
-.05pt">Inc.</span> <span style="letter-spacing:-.2pt">2009,</span> Fachinformationen</small>'' | |||
<br /> | |||
Revision as of 15:49, 15 June 2021
Prophylaxe/Prävention
Endokarditis-Prophylaxe Grundlage:
- 2015 ESC Guidelines for the management of infective Endocarditis
- ask force for the Management of Infective Endocarditis of the European Society of Cardiology
Wer:
- wird nur für Hochrisikopatienten empfohlen
- Hochrisikopatienten sind Patienten mit der höchsten Inzidenz einer infektiösen Endokarditis und/oder mit dem höchsten Risiko für einen schlechten Verlauf einer infektiösen Endokarditis. Dazu gehören:
- Patienten mit Klappenprothesen, einschließlich Transkatheterklappen, oder mit rekonstruierten Klappen unter Verwendung prothetischen Materials
- Patienten mit überstandener Endokarditis
- Patienten mit angeborenen Herzfehlern:
- jegliche zyanotischen Herzfehler
- bis zu 6 Monate nach operativer oder interventioneller Vitienkorrektur unter Verwendung von prothetischem Material oder lebenslang bei residuellem Shunt oder Klappeninsuffizienz
- Keine Endokarditis-Prophylaxe für alle anderen Formen der Klappen- und Herzerkrankungen
Wann (bei welchen Eingriffen sollten Hochrisikopatienten eine Endokarditis-Prophylaxe erhalten):
- Zahnärztliche Eingriffe
o Endokarditis-Prophylaxe empfohlen bei Eingriffen / Manipulationen an der Gingiva, der periapikalen Zahnregion oder Perforation der oralen Mukosa
o KEINE Endokarditis-Prophylaxe bei Applikation von Lokalanästhesie in reizlosem Gewebe, Faden- entfernung, Röntgen, Einsatz oder Entfernung von Zahnprothesen oder Klammern, Lippentrauma oder Verletzung der oralen Mukosa
o KEINE Endokarditis-Prophylaxe nach Milchzahnwechsel oder Verletzung der Lippen und oralen Mukosa
- Eingriffe am Respirationstrakt
Cave: KEINE Endokarditis-Prophylaxe bei Eingriffen am Respirationstrakt, einschließlich Laryngoskopie, Bronchoskopie transnasale-,
- endotracheale Intubation (oral oder nasal)
- Gastrointestinale oder Urogenitale Eingriffe an infizierten Herden
o intraabdominaler Abszess
o Ileus
o Darmperforation
o Magenperforation
o Cholecystitis/ Gallenblasenempyem
o Fourniersche Gangrän
o infizierte Harnstauungsniere
Cave: KEINE Endokarditis-Prophylaxe bei: Gastroskopie, Coloskopie, transösophageales Echo, Cystoskopie
- Eingriffe an Weichteilgewebe und Haut
o KEINE Endokarditis-Prophylaxe
PAP und Endokarditis-Prophylaxe
Liegt eine Indikation zur Endokarditis-Prophylaxe vor, werden - anstelle der oben empfohlenen Antibiotika – bevorzugt Substanzen mit Enterokokken-Wirksamkeit eingesetzt:
| Antibiotika zur PAP | Empfohlene (Ersatz-) Substanz bei Indikation zur Endokarditis-Prophylaxe |
|---|---|
| Ohne PAP-Indikation |
Ampicillin 2g i.v. |
| Cefazolin / Cefuroxim |
Ampicillin-Sulbactam 3g i.v. |
| Cefazolin / Cefuroxim + Metronidazol |
Ampicillin-Sulbactam 3g i.v. |
| ß-Laktam-Allergie | Empfohlene (Ersatz-) Substanz bei Indikation zur Endokarditis-Prophylaxe |
|---|---|
| Ohne PAP |
Clindamycin 600mg i.v./p.o. |
| Cefazolin / Cefuroxim (ohne Gastrointestinaltrakt) |
Clindamycin 600mg i.v./p.o. |
| Cefazolin / Cefuroxim +/- Metronidazol |
Vancomycin 1g i.v. + Ciprofloxacin 400 mg i.v. +/- Metronidazol 500 mg i.v. |
Antibiotika für die perioperative Antibiotika- und Endokarditis-Prophylaxe
| Antibiotikagruppe | Substanz | Dosis/Applikations-art | Zeitpunkt der Gabe | Wiederholungsgabe3) |
|---|---|---|---|---|
| Aminopenicillin |
Ampicillin |
1 x 2g i.v. |
Infusionsende 30 min vor Schnitt |
> 3 h OP-Dauer |
| Aminopenicillin +
|
Amoxicillin + Clavulan-Säure Ampicillin + Sulbactam |
1 x 875/125mg p.o. 1 x 3g i.v. |
120 min vor Schnitt1) Infusionsende 30 min vor Schnitt |
> 3 h OP-Dauer > 3 h OP-Dauer |
| gezielte Carbapenem-Prophylaxe |
Imipenem 2)
|
1 x 1g i.v
|
Infusionsende 30 min vor Schnitt |
> 3 h OP-Dauer |
| Cephalosporin Gruppe 1 |
Cefazolin |
1 x 2g i.v bei KG >120kg 1 x 3g i.v. |
Infusionsende 30 min vor Schnitt |
> 3 h OP-Dauer |
| Cephalosporin Gruppe 2 |
Cefuroxim |
1 x 1,5g i.v.
|
Infusionsende 30 min vor Schnitt |
> 3 h OP-Dauer |
Sonderindikationen
| Antibiotikagruppe | Substanz | Dosis/Applikations-art | Zeitpunkt der Gabe | Wiederholungsgabe3) |
|---|---|---|---|---|
| Cephalosporin Gruppe 3a |
Ceftriaxon |
1 x 2g i.v. |
Infusionsende 30 min vor Schnitt |
> 8 h OP- Dauer |
| Fluorchinolon Gruppe 2 |
Ciprofloxacin |
1 x 500mg p.o.
1 x 400mg i.v. |
120 min vor Schnitt1)
Infusionsende 30 min vor Schnitt, Infusionsdauer 60 min |
> 8 h OP- Dauer |
| Fluorchinolon Gruppe 3 |
Levofloxacin |
1 x 500mg p.o. |
120 min vor Schnitt1) |
> 12 h OP- Dauer |
| Glykopetid |
Vancomycin 3) |
1 x 1g i.v. |
Infusionsende 30 min vor Schnitt, Infusionsdauer >60 min3) |
> 12 h OP- Dauer |
| Folat-Antagonist |
Cotrimoxazol |
1 x 960mg p.o. |
120 min vor Schnitt1) |
> 12 h OP- Dauer |
| Lincosamid |
Clindamycin |
1 x 600mg i.v. |
Infusionsende 30 min vor Schnitt |
> 6 h OP- Dauer |
| Nitroimidazol |
Metronidazol |
1 x 500mg i.v. |
Infusionsende 30 min vor Schnitt |
> 8 h OP- Dauer |
1) Maximaler Serumspiegel bei normaler enteraler Resorption
2) „Imipenem 1g“ entspricht Imipenem 1g + Cilastatin 1g (= 2x 1Ampulle à 0,5g Imipenem + 0,5g Cilastatin)
3) Infusionsdauer > 1 h, ansonsten Gefahr von „Red-Man-Syndrom“ (Hautrötung u. Schwellung im Kopf-Hals-Bereich, die wie eine Allergie imponieren kann)
4) In Abhängigkeit von der Halbwertszeit bei normaler Nierenfunktion
Angaben Halbwertzeiten: Mandell, Douglas and Bennetts: Principles and Practise of Infectious Disease. Elsevier Inc. 2009, Fachinformationen